in Interstitial Lung Disease: An Art in Need of Science. Ann Am Thorac Soc. 2017 Sep;14(9):1373-1377. \[[PubMed: 28644693](https://pubmed.ncbi.nlm.nih.gov/28644693)\] 49. Long-Term Oxygen Treatment Trial Research Group. Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Stoller JK, Wise R, Yusen RD, Tonascia J, Sternberg AL, Bailey W. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016 Oct 27;375(17):1617-1627. \[[PMC free article: PMC5216457](/pmc/articles/PMC5216457/)\] \[[PubMed: 27783918](https://pubmed.ncbi.nlm.nih.gov/27783918)\] 50. Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021 Feb 01;2(2):CD006322. \[[PMC free article: PMC8094410](/pmc/articles/PMC8094410/)\] \[[PubMed: 34559419](https://pubmed.ncbi.nlm.nih.gov/34559419)\] 51. Nolan CM, Polgar O, Schofield SJ, Patel S, Barker RE, Walsh JA, Ingram KA, George PM, Molyneaux PL, Maher TM, Man WD. Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study. Chest. 2022 Mar;161(3):728-737. \[[PMC free article: PMC8941605](/pmc/articles/PMC8941605/)\] \[[PubMed: 34699771](https://pubmed.ncbi.nlm.nih.gov/34699771)\] 52. Marijic P, Schwarzkopf L, Maier W, Trudzinski F, Schwettmann L, Kreuter M. Effects of Influenza Vaccination in Patients with Interstitial Lung Diseases: An Epidemiological Claims Data Analysis. Ann Am Thorac Soc. 2022 Sep;19(9):1479-1488. \[[PMC free article: PMC9447394](/pmc/articles/PMC9447394/)\] \[[PubMed: 35312465](https://pubmed.ncbi.nlm.nih.gov/35312465)\] 53. Idiopathic Pulmonary Fibrosis Clinical Research Network. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24;366(21):1968-77. \[[PMC free article: PMC3422642](/pmc/articles/PMC3422642/)\] \[[PubMed: 22607134](https://pubmed.ncbi.nlm.nih.gov/22607134)\] 54. Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021 Nov;160(5):1751-1763. \[[PubMed: 34217681](https://pubmed.ncbi.nlm.nih.gov/34217681)\] 55. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Peric√†s JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V., MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 Feb 08;390(6):497-509. \[[PubMed: 38324483](https://pubmed.ncbi.nlm.nih.gov/38324483)\] 56. Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res. 2019 Mar 12;20(1):55. \[[PMC free article: PMC6416878](/pmc/articles/PMC6416878/)\] \[[PubMed: 30866942](https://pubmed.ncbi.nlm.nih.gov/30866942)\]